BioCentury
ARTICLE | Clinical News

Genomic Health reports cost-effectiveness data for colon cancer assay

January 25, 2013 1:57 AM UTC

Genomic Health Inc. (NASDAQ:GHDX) reported data from a cost-effectiveness analysis of 141 patients with stage II colon cancer showing that physicians reduced the number of recommendations for adjuvant chemotherapy by 22% after receiving results on the risk of recurrence as determined by the company's Oncotype DX colon cancer assay. The company said the reduction led to average overall direct medical care cost savings of $4,200 per patient. Data will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on Saturday.

Genomic Health launched the Oncotype DX colon cancer assay in 2010 for predicting recurrence risk in stage II colon cancer patients following surgery. The assay analyzes the expression of 12 genes to generate a Recurrence Score to predict magnitude of chemotherapy benefit and likelihood of recurrence of colon cancer. ...